Mangalam Drugs & Organics Limited (MANGALAM.NS)
INR 80.98
(-1.51%)
INR 80.98
(-1.51%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.33 Billion INR | -7.29% |
| 2022 | 3.59 Billion INR | 9.5% |
| 2021 | 3.28 Billion INR | 24.95% |
| 2020 | 2.62 Billion INR | 13.95% |
| 2019 | 2.3 Billion INR | 10.3% |
| 2018 | 2.09 Billion INR | -11.39% |
| 2017 | 2.36 Billion INR | 23.54% |
| 2016 | 1.91 Billion INR | 19.57% |
| 2015 | 1.59 Billion INR | -5.96% |
| 2014 | 1.69 Billion INR | 35.43% |
| 2013 | 1.25 Billion INR | 9.29% |
| 2012 | 1.14 Billion INR | -5.88% |
| 2011 | 1.21 Billion INR | 7.68% |
| 2010 | 1.13 Billion INR | 18.35% |
| 2009 | 956.88 Million INR | 7.05% |
| 2008 | 893.84 Million INR | 15.1% |
| 2007 | 776.6 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 3.33 Billion INR | 0.0% |
| 2023 Q2 | 3.8 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 3.33 Billion INR | -7.29% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 3.59 Billion INR | 9.5% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.74 Billion INR | 0.0% |
| 2022 Q4 | 3.59 Billion INR | 0.0% |
| 2021 Q2 | 3.31 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 3.28 Billion INR | 24.95% |
| 2021 Q4 | 3.28 Billion INR | 0.0% |
| 2020 Q4 | 2.62 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.58 Billion INR | 0.0% |
| 2020 FY | 2.62 Billion INR | 13.95% |
| 2019 FY | 2.3 Billion INR | 10.3% |
| 2019 Q4 | 2.3 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 2.14 Billion INR | 0.0% |
| 2018 Q4 | 2.09 Billion INR | 0.0% |
| 2018 FY | 2.09 Billion INR | -11.39% |
| 2018 Q2 | 2.43 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.36 Billion INR | 23.54% |
| 2017 Q4 | 2.36 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.13 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 1.91 Billion INR | 19.57% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 1.92 Billion INR | 0.0% |
| 2016 Q4 | 1.91 Billion INR | 0.0% |
| 2015 Q4 | 1.59 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.57 Billion INR | 0.0% |
| 2015 FY | 1.59 Billion INR | -5.96% |
| 2014 Q4 | 1.69 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.69 Billion INR | 35.43% |
| 2014 Q2 | 1.19 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 1.25 Billion INR | 9.29% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.13 Billion INR | 0.0% |
| 2013 Q4 | 1.25 Billion INR | 0.0% |
| 2012 FY | 1.14 Billion INR | -5.88% |
| 2012 Q4 | 1.14 Billion INR | 0.0% |
| 2011 Q4 | 1.21 Billion INR | 0.0% |
| 2011 FY | 1.21 Billion INR | 7.68% |
| 2010 FY | 1.13 Billion INR | 18.35% |
| 2009 FY | 956.88 Million INR | 7.05% |
| 2008 FY | 893.84 Million INR | 15.1% |
| 2007 FY | 776.6 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -9.322% |
| Aarti Drugs Limited | 24.32 Billion INR | 86.292% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 87.087% |
| Ajanta Pharma Limited | 46.38 Billion INR | 92.812% |
| Alembic Limited | 23.28 Billion INR | 85.682% |
| Alkem Laboratories Limited | 155.74 Billion INR | 97.859% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 94.827% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 69.071% |
| Bal Pharma Limited | 3.2 Billion INR | -4.069% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -608.167% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 72.532% |
| Brooks Laboratories Limited | 904.45 Million INR | -268.647% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -125.772% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 87.639% |
| Divi's Laboratories Limited | 154.7 Billion INR | 97.845% |
| Eris Lifesciences Limited | 70.48 Billion INR | 95.27% |
| Granules India Limited | 55.2 Billion INR | 93.961% |
| Ind-Swift Limited | 6.54 Billion INR | 49.054% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -53.596% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 91.652% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 97.113% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -38.891% |
| Medicamen Biotech Limited | 2.94 Billion INR | -13.208% |
| Medico Remedies Limited | 961.95 Million INR | -246.612% |
| Wockhardt Limited | 76.49 Billion INR | 95.641% |
| Orchid Pharma Limited | 15.53 Billion INR | 78.542% |
| RPG Life Sciences Limited | 5.12 Billion INR | 34.989% |
| Shilpa Medicare Limited | 30.93 Billion INR | 89.221% |
| Sigachi Industries Limited | 6.94 Billion INR | 51.967% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 85.791% |
| Unichem Laboratories Limited | 31.69 Billion INR | 89.48% |
| Vaishali Pharma Limited | 799.55 Million INR | -317.011% |
| Wanbury Limited | 3.43 Billion INR | 2.931% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.861% |
| FDC Limited | 24.68 Billion INR | 86.491% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 9.117% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 56.422% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.14% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 88.303% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 71.383% |
| Laurus Labs Limited | 83.87 Billion INR | 96.025% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 84.782% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -228.138% |
| Hester Biosciences Limited | 6.62 Billion INR | 49.66% |
| Ipca Laboratories Limited | 111.01 Billion INR | 96.997% |
| Venus Remedies Limited | 6.26 Billion INR | 46.808% |
| ZIM Laboratories Limited | 4.46 Billion INR | 25.379% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.26% |
| Morepen Laboratories Limited | 12.93 Billion INR | 74.217% |
| Neuland Laboratories Limited | 18.32 Billion INR | 81.806% |
| Sequent Scientific Limited | 15.4 Billion INR | 78.354% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 85.208% |
| Valiant Laboratories Limited | 3.42 Billion INR | 2.703% |
| Windlas Biotech Limited | 6.26 Billion INR | 46.755% |
| Hikal Limited | 24.87 Billion INR | 86.594% |
| Innova Captab Limited | 13.2 Billion INR | 74.757% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 58.026% |
| Themis Medicare Limited | 5.66 Billion INR | 41.134% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 85.144% |
| Mankind Pharma Limited | 119.63 Billion INR | 97.213% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 97.678% |
| Sakar Healthcare Limited | 3.88 Billion INR | 14.212% |
| Albert David Limited | 4.97 Billion INR | 33.046% |
| Lupin Limited | 239.97 Billion INR | 98.611% |
| Gufic Biosciences Limited | 10.92 Billion INR | 69.482% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.61% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 52.388% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 17.605% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.596% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 97.786% |
| NATCO Pharma Limited | 69.06 Billion INR | 95.172% |
| Suven Life Sciences Limited | 2.84 Billion INR | -17.031% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -87.133% |
| Strides Pharma Science Limited | 58.39 Billion INR | 94.29% |
| Indoco Remedies Limited | 21.44 Billion INR | 84.454% |
| Alpa Laboratories Limited | 1.82 Billion INR | -82.576% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -121.003% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 35.262% |